Skip to main content

Table 1 Patient characteristics

From: Eosinophil-cationic protein - a novel liquid prognostic biomarker in melanoma

Variables Patients with ECP higha (n = 34) Patients with ECP lowb (n = 22) p-value
Age Median (Range) 60 years (40–83 years) 64 years (31–90 years) 0.3877
OS Median (Range) 12 months (2–48 months) 28 months (3–44 months) 0.0916
  n % n %  
Gender Male 22 65 14 64 0.9350
Female 12 35 8 36
Therapy Surgery 31 91 19 86 0.6701
Interferon-alpha 13 38 7 32 0.6245
Chemotherapy 29 85 13 59 0.0270
Radiotherapy 25 74 17 77 0.7520
Signal transduction inhibitor (targeted therapy) 21 62 9 41 0.1264
Checkpoint inhibitor therapy (immunotherapy) 9 26 18 82 < 0.0001
Type of melanoma Cutaneous 20c 59 12 55 0.7520
MUP 5 15 9 41 0.0270
Uveal 3 9 1 5 > 0.9999
Mucosal 7c 21 0 0 0.0349
LDH > ULN 20 59 18 82 0.0868
< ULN 14 41 4 18
BRAF statusd V600 mutation 13 38 9e 41 0.7151
V600 wildtype 14 41 12e 55
Brain metastases (M1d) 18 53 8 36 0.2244
  1. adefined as > 16.0 ng/ml
  2. bdefined as < 16.0 ng/ml
  3. cone patient has both, cutaneous and mucosal melanoma
  4. dBRAF status of 7 patients was not tested, BRAF test result of one patient was not evaluable
  5. eone patient has discrepant test results of two distinct metastases one with V600E mutation and one with wildtype